Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world.Novo has recently completed the acquisition of Akero in a deal valued at up to $5.2 billion. This acquisition adds Akero's efruxifermin to Novo's already impressive portfolio. The FDA breakthrough drugs continue to show promise, with nearly three quarters of designated drugs being approved, especially in the rare disease and cancer categories.In other news, there has been a delay in an ACIP meeting, Ferring has announced layoffs of 500 employees, and Pfizer has emerged victorious in a takeover bid against other suitors. Experts in the field are actively researching new avenues for scalability and cost reduction in cell therapy production. Upcoming events to look out for include webinars on transforming digital sequences into mRNA and the future of mRNA medicine.

Support the show